Literature DB >> 17934711

[Neuromyelitis optica].

S Jarius1, B Wildemann.   

Abstract

Neuromyelitis optica (NMO, Devic syndrome) is a rare demyelinating disease of the central nervous system which mostly follows a relapsing course. Key features of this disorder include unilateral or bilateral optic neuritis and longitudinally extensive myelitis (> or = three segments). Brain lesions are rarely present at onset. They may however evolve during the course of disease but usually remain asymptomatic. The histopathology of NMO is suggestive of an underlying humoral autoimmune pathomechanism and indicates that NMO is a distinct entity rather than a variant of multiple sclerosis. The recent detection of NMO-specific serum autoantibodies against the water channel aquaporin-4 (Aqp4) is of significant diagnostic relevance and classifies NMO as the first inflammatory demyelinating disorder of the CNS with a defined autoantigen. More recent therapeutic strategies such as plasma exchange or pharmacological B-cell depletion are expected to improve long-term prognosis of NMO.

Entities:  

Mesh:

Year:  2007        PMID: 17934711     DOI: 10.1007/s00115-007-2262-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  91 in total

1.  Aquaporin subtypes in rat cerebral microvessels.

Authors:  H Kobayashi; S Minami; S Itoh; S Shiraishi; H Yokoo; T Yanagita; Y Uezono; M Mohri; A Wada
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

2.  Cerebrospinal fluid findings in Devic's neuromyelitis optica.

Authors:  M Zaffaroni
Journal:  Neurol Sci       Date:  2004-11       Impact factor: 3.307

3.  Fulminant Devic disease successfully treated by lymphocytapheresis.

Authors:  I Nozaki; T Hamaguchi; K Komai; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-13       Impact factor: 10.154

4.  Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica.

Authors:  C S Yu; F C Lin; K C Li; T Z Jiang; C Z Zhu; W Qin; H Sun; P Chan
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

5.  NMO-IgG in the diagnosis of neuromyelitis optica.

Authors:  S Jarius; D Franciotta; R Bergamaschi; H Wright; E Littleton; J Palace; R Hohlfeld; A Vincent
Journal:  Neurology       Date:  2007-02-07       Impact factor: 9.910

6.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

7.  Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Authors:  Jacqueline Bakker; Luanne Metz
Journal:  Can J Neurol Sci       Date:  2004-05       Impact factor: 2.104

8.  Devic's neuromyelitis optica: a clinicopathological study of 8 patients.

Authors:  R N Mandler; L E Davis; D R Jeffery; M Kornfeld
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

9.  Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

Authors:  J M Fidler; S Q DeJoy; J J Gibbons
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  7 in total

1.  Retinal ganglion cell-inner plexiform and nerve fiber layers in neuromyelitis optica.

Authors:  Sai-Jing Hu; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

2.  Homology between Klebsiella pneumoniae and human aquaporin-4: no evidence for cross-reactivity in neuromyelitis optica. A study on 114 patients.

Authors:  S Jarius; K P Wandinger; S Platzer; B Wildemann
Journal:  J Neurol       Date:  2010-12-02       Impact factor: 4.849

3.  [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Authors:  C Trebst; A Berthele; S Jarius; T Kümpfel; S Schippling; B Wildemann; C Wilke
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 4.  [Neuromyelitis optica].

Authors:  B Wildemann; S Jarius; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 5.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 6.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Authors:  Corinna Trebst; Sven Jarius; Achim Berthele; Friedemann Paul; Sven Schippling; Brigitte Wildemann; Nadja Borisow; Ingo Kleiter; Orhan Aktas; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

Review 7.  The Glymphatic System (En)during Inflammation.

Authors:  Frida Lind-Holm Mogensen; Christine Delle; Maiken Nedergaard
Journal:  Int J Mol Sci       Date:  2021-07-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.